Visible Genetics, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Genotyping kits for hepatitis B and C will be available for research use on VGI's OpenGene DNA sequencing system early in 2002, the firm predicts. The Toronto firm gained 510(k) clearance for its Trugene HIV-1 genotyping kit for use with the system on Sept. 26 (1"The Gray Sheet" Sept. 3, 2001, p. 10). The first HIV drug-resistance test available in the U.S., the test includes software to aid in antiretroviral drug selection. The hepatitis tests will tell physicians which variant of hepatitis B or C is afflicting the patient